Work Here?
Overview
Harrow focuses on eyecare pharmaceuticals, combining a compounding business (ImprimisRx) with a portfolio of FDA-approved branded drugs and biosimilars, plus biotech investments. Its products include customized compounded sterile and topical eye medications delivered directly to physicians and patients, alongside branded drugs acquired from other companies. The company differentiates itself by integrating a direct-to-physician compounding platform with an expanding branded drug portfolio, biosimilars, and owned production and distribution facilities across all 50 states. Its goal is to provide accessible, high-quality eye medications and grow its commercial and biotech assets to serve surgeons, hospitals, and patients nationwide.
About Harrow
Industries
Biotechnology
Healthcare
Company Size
201-500
Company Stage
IPO
Headquarters
Nashville, Tennessee
Founded
1998
People at Harrow
People at Harrow who can refer or advise you
Simplify's Take
What believers are saying
- BYOOVIZ launch in July 2026 secures entry into the $9B anti-VEGF market as the first interchangeable ophthalmic biosimilar.
- VERKAZIA relaunch targets pediatric VKC with a steroid-sparing calcineurin inhibitor, reducing glaucoma and cataract risks from steroid rescue.
- Melt acquisition adds MELT-300, a sublingual midazolam-ketamine candidate with Phase 3 superiority, targeting NDA submission in H1 2027.
What critics are saying
- VEVYE revenue erosion from high-deductible patients and CVS Tier 1 reclassification caused an $8M gross-to-net hit in Q1 2026.
- FDA crackdown on non-approved sterile formulations threatens ImprimisRx compounding revenue, with state pharmacy audits targeting dry eye and glaucoma drugs.
- MELT-300 NDA rejection due to FDA ketamine neurotoxicity concerns could trigger a $50M debt covenant breach and kill a $200M+ pipeline.
What makes Harrow unique
- Harrow is the only U.S. ophthalmic firm with exclusive rights to BYOOVIZ and OPUVIZ biosimilars from Samsung Bioepis.
- It uniquely combines FDA-approved branded drugs, a compounding pharmacy ImprimisRx, and a biotech incubator for late-stage ocular assets.
- Harrow holds exclusive U.S. commercial rights to pipeline biosimilars BYOOVIZ and OPUVIZ after Samsung Bioepis regained rights from Biogen.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$573.7M
Above
Industry Average
Funded Over
10 Rounds
Benefits
Remote Work Options
Stock Price
Growth & Insights and Company News
6 month growth
↑ 29%1 year growth
↑ 29%2 year growth
↑ 29%Harrow, Inc. recently completed a private fixed‑income offering of US$50,000,000 in 8.625% senior unsecured notes due 2030, callable and guaranteed by its wholly owned domestic restricted subsidiaries, under Regulation S and Rule 144A. The additional 2030 notes give Harrow more financial flexibility to fund growth initiatives, product development, and future business development opportunities without issuing new equity. We’ll now examine how this US$50,000,000 senior unsecured notes issuance...
Harrow reported fourth-quarter earnings of $0.26 per share, missing the Zacks Consensus Estimate of $0.40 per share, representing a 34.46% negative surprise. This compares to earnings of $0.25 per share in the same period last year. The pharmaceutical and drug compounding company posted revenues of $89.09 million for the quarter ended December 2025, slightly exceeding the Zacks Consensus Estimate by 0.33% and up from $66.83 million a year earlier. Over the last four quarters, Harrow has surpassed consensus earnings estimates twice and topped revenue estimates once. Harrow shares have gained 10.6% year-to-date, outperforming the S&P 500's 0.5% gain. However, unfavorable estimate revision trends have resulted in a Zacks Rank of 4 (Sell), suggesting potential near-term underperformance.
Harrow, a North American ophthalmic disease management solutions provider, reported record fourth-quarter revenue of $89.1 million, up 33% year-over-year, and full-year 2025 revenue of $272.3 million, up 36% from 2024. The company posted GAAP net income of $6.6 million in Q4 but a full-year net loss of $5.1 million. Adjusted EBITDA reached $24.2 million in Q4 and $61.9 million for the full year. Harrow generated $43.9 million in operating cash flow for 2025, compared to $22.2 million used in operations in 2024. The company provided 2026 guidance of $350 million to $365 million in revenue and $80 million to $100 million in Adjusted EBITDA. Harrow plans to double sales teams for key products and expand commercial operations whilst advancing its development pipeline.
Harrow (Nasdaq: HROW) has completed its acquisition of Melt Pharmaceuticals, adding clinical-stage candidates MELT-210, MELT-300, and MELT-400. MELT-300, a sublingual midazolam and ketamine formulation, showed statistical superiority in Phase 2 and 3 trials. Harrow plans to submit an NDA in H1 2027, targeting approval in H1 2028 and commercial launch in H2 2028. Over 800 U.S. ophthalmic institutions currently use Harrow's MKO Melt product.
Harrow Health ( ($HROW) ) just unveiled an update. On September 26, 2025, Harrow, Inc. entered into a New Credit Agreement with Fifth Third Bank for a senior secure...
Harrow is Hiring for 27 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Harrow
Industries
Biotechnology
Healthcare
Company Size
201-500
Company Stage
IPO
Headquarters
Nashville, Tennessee
Founded
1998
Harrow is Hiring for 27 Jobs on Simplify!
Find jobs on Simplify and start your career today